@article{afa5038483a64cf7a2c02dd342cd14c5,
title = "Lessons for the HIV response from structural innovations catalysed by COVID-19",
keywords = "COVID-19, HIV, Public Health",
author = "Michael Isbell and Bekker, {Linda Gail} and Beatriz Grinsztejn and Jennifer Kates and Adeeba Kamarulzaman and Lewin, {Sharon R.} and Kenneth Ngure and Nittaya Phanuphak and Anton Pozniak and Anna Grimsrud",
note = "Funding Information: LGB is in receipt of honoraria from Merck PTY LTD, ViiV Healthcare and Gilead Sciences for advisory work unrelated to this manuscript. KN receives grants or contracts from the National Institutes of Health, Bill & Melinda Gates Foundation and Merck Investigator Studies Program (MISP), payment or honoraria from Gilead Sciences Inc and support for attending meetings and/or travel from IAS—the International AIDS Society to attend IAS and AIDS Conferences, the IMPAACT Network support to attend the annual meeting and HANC support to attend annual network meeting. AP receives grants or contracts from Gilead Sciences, consulting fees, payment or honoraria from Gilead, ViiV, Merck and Janssen. MI receives all support for the present manuscript and consulting fees from IAS—the International AIDS Society. JK receives grants or contracts from the Gates Foundation, support for attending meetings and/or travel from IAS—the International AIDS Society to attend IAS and AIDS Conferences, and is a member and treasurer of the Governing Council of IAS—the International AIDS Society. SRL receives all support for the present manuscript from the National Health and Medical Research Council (NHMRC), grants or contracts from, National Institutes of Health (NIH), Medical Research Future Fund, Gandel Foundation, Doherty Sino Australia COVID-19 Partnership Fund, Victorian Government Department of Jobs, Precincts and Regions (DJPR), American Foundation of AIDS Research (amfAR), Gilead Sciences, Australian Center for HIV and Hepatitis Virology Research (ACH2), Wellcome Trust, NHMRC, Leidos, Merck, Melbourne HIV Cure Consortium (Victorian state government), mRNA Victorian Research Accelerator Fund and Medical Research Future Fund, consulting fees from Abivax, GeoVax, ViiV, TetraLogic, Vaxxinity, Esfam, and Immunocore, and payment or honoraria from Gilead Sciences, Briston Myers Squibb, Merck. SRL also filled in 2017 International PCT patent (PCTAU2017050631) and participates on these advisory boards, Abivax, Bionor, ViiV, Calimmune, InnaVirVax, Aelix Therapeutics, Immunocore, French Agency for Research on AIDS and Viral Hepatitis (ANRS) Emerging Infectious Diseases. AG, AK, NP, BG and L-GB declare no competing interests. Funding Information: AG is supported by the Bill & Melinda Gates Foundation (INV002610). ",
year = "2022",
month = nov,
day = "29",
doi = "10.1136/bmjgh-2022-010854",
language = "English",
volume = "7",
journal = "BMJ Global Health",
issn = "2059-7908",
publisher = "BMJ",
number = "11",
}
